The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: Results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

Research output: Contribution to journalArticlepeer-review

Standard

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia : Results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. / Burnett, A. K.; Hills, R. K.; Hunter, A. E.; Milligan, D.; Kell, W. J.; Wheatley, K.; Yin, J.; McMullin, M. F.; Dignum, H.; Bowen, D.; Russell, N. H.

In: Leukemia, Vol. 27, No. 1, 01.01.2013, p. 75-81.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{9c0080cec5a54493926c1f2563f46aa5,
title = "The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: Results from the LRF AML14 and NCRI AML16 pick-a-winner comparison",
abstract = "The treatment of older patients with acute myeloid leukaemia, who are not considered suitable for conventional intensive therapy, is unsatisfactory. Low-dose Ara-C(LDAC) has been established as superior to best supportive care, but only benefits the few patients who enter complete remission. Alternative or additional treatments are required to improve the situation. This randomised trial compared the addition of the immunoconjugate, gemtuzumab ozogamicin (GO), at a dose of 5 mg on day 1 of each course of LDAC, with the intention of improving the remission rate and consequently survival. Between June 2004 and June 2010, 495 patients entered the randomisation. The addition of GO significantly improved the remission rate (30% vs 17%; odds ratio(OR) 0.48 (0.32-0.73); P=0.006), but not the 12 month overall survival (25% vs 27%). The reason for the induction benefit failing to improve OS was two-fold: survival of patients in the LDAC arm who did not enter remission and survival after relapse were both superior in the LDAC arm. Although the addition of GO to LDAC doubled the remission rate it did not improve overall survival. Maintaining remission in older patients remains elusive.",
keywords = "AML, clinical trial, gemtuzumab ozogamicin",
author = "Burnett, {A. K.} and Hills, {R. K.} and Hunter, {A. E.} and D. Milligan and Kell, {W. J.} and K. Wheatley and J. Yin and McMullin, {M. F.} and H. Dignum and D. Bowen and Russell, {N. H.}",
year = "2013",
month = jan,
day = "1",
doi = "10.1038/leu.2012.229",
language = "English",
volume = "27",
pages = "75--81",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia

T2 - Results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

AU - Burnett, A. K.

AU - Hills, R. K.

AU - Hunter, A. E.

AU - Milligan, D.

AU - Kell, W. J.

AU - Wheatley, K.

AU - Yin, J.

AU - McMullin, M. F.

AU - Dignum, H.

AU - Bowen, D.

AU - Russell, N. H.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The treatment of older patients with acute myeloid leukaemia, who are not considered suitable for conventional intensive therapy, is unsatisfactory. Low-dose Ara-C(LDAC) has been established as superior to best supportive care, but only benefits the few patients who enter complete remission. Alternative or additional treatments are required to improve the situation. This randomised trial compared the addition of the immunoconjugate, gemtuzumab ozogamicin (GO), at a dose of 5 mg on day 1 of each course of LDAC, with the intention of improving the remission rate and consequently survival. Between June 2004 and June 2010, 495 patients entered the randomisation. The addition of GO significantly improved the remission rate (30% vs 17%; odds ratio(OR) 0.48 (0.32-0.73); P=0.006), but not the 12 month overall survival (25% vs 27%). The reason for the induction benefit failing to improve OS was two-fold: survival of patients in the LDAC arm who did not enter remission and survival after relapse were both superior in the LDAC arm. Although the addition of GO to LDAC doubled the remission rate it did not improve overall survival. Maintaining remission in older patients remains elusive.

AB - The treatment of older patients with acute myeloid leukaemia, who are not considered suitable for conventional intensive therapy, is unsatisfactory. Low-dose Ara-C(LDAC) has been established as superior to best supportive care, but only benefits the few patients who enter complete remission. Alternative or additional treatments are required to improve the situation. This randomised trial compared the addition of the immunoconjugate, gemtuzumab ozogamicin (GO), at a dose of 5 mg on day 1 of each course of LDAC, with the intention of improving the remission rate and consequently survival. Between June 2004 and June 2010, 495 patients entered the randomisation. The addition of GO significantly improved the remission rate (30% vs 17%; odds ratio(OR) 0.48 (0.32-0.73); P=0.006), but not the 12 month overall survival (25% vs 27%). The reason for the induction benefit failing to improve OS was two-fold: survival of patients in the LDAC arm who did not enter remission and survival after relapse were both superior in the LDAC arm. Although the addition of GO to LDAC doubled the remission rate it did not improve overall survival. Maintaining remission in older patients remains elusive.

KW - AML

KW - clinical trial

KW - gemtuzumab ozogamicin

UR - http://www.scopus.com/inward/record.url?scp=84873409057&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.229

DO - 10.1038/leu.2012.229

M3 - Article

C2 - 22964882

AN - SCOPUS:84873409057

VL - 27

SP - 75

EP - 81

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -